Skip to content
Published findings, with room for what remains unknown.
Rx Tesamorelin

Tesamorelin and organ fat through the trial data; we write no scripts.

An overhead breakfast table with hands reaching in from the edges.

Tesamorelin and the fat around the organs

Fat around the organs differs from fat beneath the skin. That distinction matters when reading the evidence.

Tesamorelin basics

What tesamorelin changes

Tesamorelin is a synthetic version of growth hormone-releasing hormone, a signal that tells the pituitary gland to release growth hormone. That response also raises IGF-1, a growth factor. The main human trials examined deep abdominal fat in adults living with HIV.

The approved indication is excess abdominal fat in adults with HIV-associated lipodystrophy, a change in body-fat distribution. The label does not describe a general weight-loss treatment. A smaller fat compartment and a lower body weight are different outcomes.

A cropped side view of an adult reaching for a sweater beside a chair.

CT scans can measure both the amount of fat and its density. The fat-quality analysis asks what changed in tissue beyond its size, including fat beneath the skin.

An adult's hands setting a plate of greens and a halved lemon on a stone kitchen counter.

Fat stored inside the liver is a separate measurement. Small trials in people with HIV found reductions, while longer-term questions about liver health remain open.

Hands turning a page at a stone desk beside a closed notebook and pencil.

A published trial amount belongs to a particular study and preparation. Read the regimen alongside its participants, duration, and safety checks, rather than as personal instructions.

A result in a defined population

In the 26-week trial of 412 adults with HIV, visceral fat fell 15.2% with tesamorelin and rose 5.0% with placebo. Visceral fat means the fat surrounding abdominal organs. Those results do not establish the same effect in people without HIV.

In the longer follow-up, fat returned after treatment stopped. A favorable scan during a trial leaves questions about what happens over the years that follow.

Tesamorelin vs sermorelin

Both compounds act through growth hormone-releasing hormone signaling. Their structures and clinical records differ. Tesamorelin’s placebo-controlled fat studies cannot establish that it works better than sermorelin. The comparison separates what the molecules share from what researchers actually tested.

Compare the evidence
An adult in profile tending green leaves beside a pale stone courtyard wall.

Read the evidence in context

Three questions help place a finding: who took part, what changed, and what the measurement cannot establish. The research pages keep those details beside the result.

Tesamorelin research

Hormone responses, trial findings, and the safety cautions that still matter.

References

The publications and official medicine records behind the linked findings.

About this guide

The scope of the pages and how to read their evidence limits.